Top

Journal of Cachexia, Sarcopenia and Muscle

Published in:

01-12-2012 | Original Article

Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers

Authors: Anne E. Utech, Eiriny M. Tadros, Teresa G. Hayes, Jose M. Garcia

Published in: Journal of Cachexia, Sarcopenia and Muscle | Issue 4/2012

Abstract

Background

Cancer can lead to weight loss, anorexia, and poor nutritional status, which are associated with decreased survival in cancer patients.

Methods

Male cancer patients (n = 136) were followed for a mean time of 4.5 years. Variables were obtained at baseline: cancer stage, albumin, hemoglobin, tumor necrosis factor alpha (TNF-α), interleukin (IL)-6, bioavailable testosterone, appetite questionnaire, and weight change from baseline to 18 months. Primary statistical tests included Kaplan–Meier survival analysis and Cox proportional hazard regression (PHREG).

Results

Univariate PHREG showed that cancer stage, albumin, hemoglobin, TNF-α, IL-6, and weight change were each significantly associated with mortality risk (P < 0.05), but bioavailable testosterone was not. Multivariate PHREG analysis established that weight change and albumin were jointly statistically significant even after adjusting for stage.

Conclusion

In this sample of male oncology patients, cancer stage, serum albumin, and weight loss predicted survival. High levels of inflammatory markers and hemoglobin are associated with increased mortality, but do not significantly improve the ability to predict survival above and beyond cancer stage, albumin, and weight loss.

Available only for authorised users

Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26.PubMedCrossRef

Maltoni M, Nanni O, Pirovano M, Scarpi E, Indelli M, Martini C, et al. Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian multicenter study group on palliative care. J Pain Symptom Manage. 1999;17:240–7.PubMedCrossRef

Strasser F, Bruera ED. Update on anorexia and cachexia. Hematol Oncol Clin North Am. 2002;16:589–617.PubMedCrossRef

Sonti G, Ilyin SE, Plata-Salaman CR. Anorexia induced by cytokine interactions at pathophysiological concentrations. Am J Physiol. 1996;270:R1394–402.PubMed

Opara EI, Laviano A, Meguid MM. Correlation between food intake and cerebrospinal fluid interleukin 1 alpha in anorectic tumor-bearing rats. Nutrition. 1995;11:678–9.PubMed

Laviano A, Gleason JR, Meguid MM, Yang ZJ, Cangiano C, Rossi Fanelli F. Effects of intra-VMN mianserin and IL-1ra on meal number in anorectic tumor-bearing rats. J Investig Med. 2000;48:40–8.PubMed

Jatoi A, Daly BD, Hughes VA, Dallal GE, Kehayias J, Roubenoff R. Do patients with nonmetastatic non-small cell lung cancer demonstrate altered resting energy expenditure? Ann Thorac Surg. 2001;72:348–51.PubMedCrossRef

Vigano A, Bruera E, Jhangri GS, Newman SC, Fields AL, Suarez-Almazor ME. Clinical survival predictors in patients with advanced cancer. Arch Intern Med. 2000;160:861–8.PubMedCrossRef

Garcia JM, Garcia-Touza M, Hijazi RA, Taffet G, Epner D, Mann D, et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab. 2005;90:2920–6.PubMedCrossRef

10.

Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002;2:862–71.PubMedCrossRef

11.

Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace Jr D, Corey E. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer. 2003;97:1211–6.PubMedCrossRef

12.

Lee BN, Dantzer R, Langley KE, Bennett GJ, Dougherty PM, Dunn AJ, et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation. 2004;11:279–92.PubMedCrossRef

13.

Lyngso D, Simonsen L, Bulow J. Metabolic effects of interleukin-6 in human splanchnic and adipose tissue. J Physiol. 2002;543:379–86.PubMedCrossRef

14.

Homsi J, Luong D. Symptoms and survival in patients with advanced disease. J Palliat Med. 2007;10:904–9.PubMedCrossRef

15.

Laviano A, Meguid MM. Nutritional issues in cancer management. Nutrition. 1996;12:358–71.PubMedCrossRef

16.

Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27:793–9.PubMedCrossRef

17.

Garcia JM, Li H, Mann D, Epner D, Hayes TG, Marcelli M, et al. Hypogonadism in male patients with cancer. Cancer. 2006;106:2583–91.PubMedCrossRef

18.

Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7:6–9.PubMed

19.

Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer. 2000;88:2164–71.PubMedCrossRef

20.

Heedman PA, Strang P. Symptom assessment in advanced palliative home care for cancer patients using the ESAS: clinical aspects. Anticancer Res. 2001;21:4077–82.PubMed

21.

Genealogy Inc. Death master file [database on the Internet]. 2005. http://www.segenealogy.com/_search/vital_ssdi.htm. Accessed 7 Aug 2010.

22.

Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69:491–7.PubMedCrossRef

23.

Reuben DB, Mor V, Hiris J. Clinical symptoms and length of survival in patients with terminal cancer. Arch Intern Med. 1988;148:1586–91.PubMedCrossRef

24.

Vigano A, Donaldson N, Higginson IJ, Bruera E, Mahmud S, Suarez-Almazor M. Quality of life and survival prediction in terminal cancer patients: a multicenter study. Cancer. 2004;101:1090–8.PubMedCrossRef

25.

Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer. 2004;100:851–8.PubMedCrossRef

26.

Fouladiun M, Korner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care—correlations with food intake, metabolism, exercise capacity, and hormones. Cancer. 2005;103:2189–98.PubMedCrossRef

27.

Simons JP, Schols AM, Buurman WA, Wouters EF. Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci (Lond). 1999;97:215–23.CrossRef

28.

Tas F, Duranyildiz D, Argon A, Oguz H, Camlica H, Yasasever V, et al. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med Oncol. 2005;22:353–8.PubMedCrossRef

29.

Dulger H, Alici S, Sekeroglu MR, Erkog R, Ozbek H, Noyan T, et al. Serum levels of leptin and proinflammatory cytokines in patients with gastrointestinal cancer. Int J Clin Pract. 2004;58:545–9.PubMedCrossRef

30.

Yeh SS, Hafner A, Chang CK, Levine DM, Parker TS, Schuster MW. Risk factors relating blood markers of inflammation and nutritional status to survival in cachectic geriatric patients in a randomized clinical trial. J Am Geriatr Soc. 2004;52:1708–12.PubMedCrossRef

31.

Levine JA, Morgan MY. Preservation of macronutrient preferences in cancer anorexia. Br J Cancer. 1998;78:579–81.PubMedCrossRef

32.

Strasser F, Palmer JL, Schover LR, Yusuf SW, Pisters K, Vassilopoulou-Sellin R, et al. The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. Cancer. 2006;107:2949–57.PubMedCrossRef

33.

Del Fabbro E, Hui D, Nooruddin ZI, Dalal S, Dev R, Freer G, et al. Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report. J Pain Symptom Manage. 2010;39:1016–24.PubMedCrossRef

34.

Taira AV, Merrick GS, Galbreath RW, Butler WM, Wallner KE, Allen ZA, et al. Pretreatment serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy. Int J Radiat Oncol Biol Phys. 2009;74:1143–9.PubMedCrossRef

35.

von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle. 2010;1:7–8.CrossRef

Title: Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers
Authors: Anne E. Utech
Eiriny M. Tadros
Teresa G. Hayes
Jose M. Garcia
Publication date: 01-12-2012
Publisher: Springer-Verlag
Published in: Journal of Cachexia, Sarcopenia and Muscle / Issue 4/2012
Print ISSN: 2190-5991
Electronic ISSN: 2190-6009
DOI: https://doi.org/10.1007/s13539-012-0075-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2012

Research on cachexia, sarcopenia and skeletal muscle in cardiology

From muscle wasting to sarcopenia and myopenia: update 2012

Cancer cachexia is associated with a decrease in skeletal muscle mitochondrial oxidative capacities without alteration of ATP production efficiency

Ursodeoxycholic acid and its emerging role in attenuation of tumor growth in gastrointestinal malignancies

Consilience in sarcopenia of cirrhosis

Cancer cachexia and anabolic interventions: a case report

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials